Poster Session B  
Tuesday, October 3, 2017  
12:30 p.m.–3:00 p.m.  
Grand Ballroom 3–4

B01 Gene expression network based identification of drugs targeting advanced ovarian cancer. Sarah Walker, Dana-Farber Cancer Institute, Boston, MA, United States.

B02 Influence of germline BRCA mutation on response to oral cyclophosphamide in relapsed heavily pre-treated ovarian cancer. Pavlina Spiliopoulou, Beatson West of Scotland Cancer Centre, Glasgow, Scotland.

B03 Targeting the KIF11/KIF15/TPX2 axis to develop new therapies for ovarian cancer. Rebecca Wates, University of Kansas Medical Center, Kansas City, KS, United States.

B04 The bromodomain inhibitor INCB054329 enhances olaparib response in ovarian cancer cells by reducing homologous recombination efficiency. Andrew Wilson, Vanderbilt University Medical Center, Nashville, TN, United States.

B05 Cloning and vulnerability of intrinsically resistant subset of ovarian cancer stem cells. Jingzhong Xie, University of Houston, Houston, TX, United States.

B06, PR08 Longitudinal sampling of ctDNA reveals actionable mutations to optimize treatment of patients with high-grade serous ovarian cancer. Kaiyang Zhang, University of Helsinki, Helsinki, Finland.

B07 Targeting DAB2IP in ovarian cancer stem cells. Xingyue Zong, Indiana University, Bloomington, IN, United States.


B09 IGF axis plays apivotal role in the ovulation-induced malignant transformation of fallopian tube fimbrial epithelial cells. Tang-Yuan Chu, Department of Obstetrics & Gynecology, Buddhist Tzu Chi General Hospital, Tzu Chi University, Huiien, Taiwan.

B10, PR09 Derivation and validation of a serum diagnostic test for ovarian cancer using miRNA-seq. Kevin Elias, Brigham and Women's Hospital, Boston, MA, United States.


B12 Differences in neoplastic transformation potential between OSE and FTE. Sophia George, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, United States.

B13 Type II diabetes, related traits, and ovarian cancer risk: A Mendelian randomization analysis. Holly Harris, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.

B14 IGF axis proteins are the main carcinogens in ovulatory follicular fluid: Evidences from a mammary fat pad tumorigenesis model. Hsuan-Shun Huang, Center of Gynecological Cancers, Dep. of Research, Buddhist Tzu Chi General Hospital, Huiien, Taiwan.
B15 A cancer specific detection of serum CA125 improves differential diagnosis of epithelial ovarian cancer from benign conditions. Kaisa Huhtinen, University of Turku, Turku, Finland.

B16 The effects of estrogen-progestin combined hormone therapy on risk of ovarian cancer. Alice Lee, California State University, Fullerton, Fullerton, CA, United States.

B17 Differential protein expression patterns in vaginal swabs of patients with high-grade serous ovarian cancer. Danielle Llaneza, University of Virginia, Charlottesville, VA, United States.

B18, PR10 Breastfeeding protects against epithelial ovarian cancer: Results of the HOPE Study. Francesmary Modugno, University of Pittsburgh, Pittsburgh, PA, United States.

B19 Genome-wide association study of cancer antigen 125. Naoko Sasamoto, Brigham and Women's Hospital, Boston, MA, United States.


B21 C-reactive protein and ovarian cancer risk in the Ovarian Cancer Cohort Consortium. Shelley Tworoger, Moffitt Cancer Center, Tampa, FL, United States.

B22 Capturing L1 retrotransposon-mediated DNA transductions in endometriosis associated ovarian cancers as a way to track tumor development. Zhouchunyang Xia, University of British Columbia, Vancouver, BC, Canada.

B23 The evolution of estrogen receptor signaling in the progression of endometriosis to endometriosis-associated ovarian cancer. Michelle Boisen, Magee-Womens Hospital of UPMC, Pittsburgh, PA, United States.

B24, PR11 The driver mutational landscape of ovarian squamous cell carcinomas arising in mature cystic teratoma. Darren Ennis, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.


B26 Immune-active microenvironment in SCCOHT: rationale for therapy with immune checkpoint blockade. Elke Van Oudenhove, New York University School of Medicine, New York, NY, United States.

B27 Proteomics identifies CT45 as a mediator of chemosensitivity and immunotherapy target in ovarian cancer. Marion Curtis, University of Chicago, Chicago, IL, United States.
B28 Targeting the tumor associated carbohydrate antigen STn with humanized anti-Sialyl-Tn monoclonal antibody-drug conjugates inhibits ovarian cancer tumor growth in vitro and in vivo. Daniel Dransfield, Siamab Therapeutics, Newton, MA, United States.

B29 Cisplatin is pro-immunogenic and promotes intrinsic and reactive immune suppression in inflamed and non-inflamed ovarian cancer mouse models. Shannon Grabosch, Magee-Womens Hospital of UPMC, Pittsburgh, PA, United States.

B30 Oncolytic adenovirus infection leads to contact-dependent activation of Natural Killer cells and augments virotherapy effectiveness for ovarian cancer. Elaine Leung, Institute of Cancer Sciences, Glasgow, United Kingdom.

B31 Tumor intrinsic B7-H3 regulates drug resistance, metabolism and pathogenesis in ovarian cancer. Luciana Madeira da Silva, University of South Alabama, Mobile, AL, United States.

B32 Myeloid derived suppressor cell depletion augments antitumor activity in ovarian cancer. Ramandeep Rattan, Henry Ford Hospital, Detroit, MI, United States.

B33 Neo-epitope peptide vaccines and immune checkpoint blockade in a new preclinical ovarian cancer model. Malcolm Ross, University of Pittsburgh Medical Center, Pittsburgh, PA, United States.

B34, PR12 Epigenetic reprograming promotes an immunogenic ovarian tumor microenvironment and synergizes with adoptive transfer of engineered T cells expressing NY-ESO-1 specific T cell receptors. Li Shen, Roswell Park Cancer Institute, Buffalo, NY, United States.

B35 Australian Ovarian Cancer Assortment Trial – Allocating ovarian cancer patients into clinical trials based on molecular profiling. George Au-Yeung, Peter MacCallum Cancer Centre, Melbourne, Australia.

B36 FOXM1 induces DNA replication stress, and its bidirectional gene partner RHNO1 participates in the DNA replication stress response, in high-grade serous ovarian cancer. Carter Barger, University of Nebraska Medical Center, Omaha, NE, United States.


B38 Synergistic effects of SHP2 and PI3K inhibitors in GAB2-overexpressing ovarian cancer. Hiu Wing Cheung, Medical University of South Carolina, Charleston, SC, United States.


B40 High-throughput screening of new potential targets for high-grade serous ovarian cancer treatment. Jun Dai, Medicum, University of Helsinki, Helsinki, Finland.
B41 Studying the effect of germline polymorphisms on somatic hotspot mutations in TP53 for the treatment of high-grade serous ovarian carcinoma. Cristabelle Madona de Souza, Kansas University Medical Center, Kansas City, KS, United States.

B42 The cell adhesion molecule, L1CAM, is important for the dissemination and metastasis of fallopian tube precursor lesions. Kai Doberstein, University of Pennsylvania, Perelman School of Medicine, Ovarian Cancer Research Center, Philadelphia, PA, United States.

B43 Disruption of the YAP-LATS2 feedback loop switches ovarian cells from YAP-induced senescence to malignant transformation. Chunbo He, University of Nebraska Medical Center, Omaha, NE, United States.

B44 Early loss of monoubiquitylation of H2B alters key metabolic and immune signaling pathways promoting the progression of high-grade serous ovarian cancer. Jagmohan Hooda, University of Pennsylvania, Philadelphia, PA, United States.

B45 Amplification of ADNP and CEP250 promotes poor prognosis in high-grade serous ovarian cancer. Kubra Karagoz, Cancer Institute of New Jersey, New Brunswick, NJ, United States.

B46 DICER1 and FOXL2 mutations correlate with clinicopathologic features of ovarian Sertoli-Leydig cell tumors. Anthony Karnezis, University of British Columbia, Vancouver, BC, Canada.

B47 Rgnen (p190RhoGEF/Arhgef28) loss impairs ovarian tumor metastatic growth. Elizabeth Kleinschmidt, UC San Diego, La Jolla, CA, United States.

B48 Recurrent gene fusions are common in high-grade serous ovarian cancer. Rainer Lehtonen, University of Helsinki, Helsinki, Finland.

B49 The role Of LATS kinases in regulation of CDK4/6 in ovarian cancer. Larisa Litovchick, Virginia Commonwealth University, Richmond, VA, United States.

B50 YAP induces development of mesenchymal subtype of high grade serous ovarian cancer from granulosa cells. Xiangmin Lv, Massachusetts General Hospital, Boston, MA, United States.

B51 Mutant p53-UCHL1 axis regulates proteasome machinery and promotes high-grade serous ovarian cancer progression. Sumegha Mitra, Medical Sciences Program, Indiana University School of Medicine, Bloomington, IN, United States.

B52 Multifunctional adipokine Apelin/APJ pathway cell autonomously promotes ovarian cancer tumorigenesis. Deepika Neelakantan, University of Oklahoma HSC, Oklahoma City, OK, United States.

**Poster Session B**

Tuesday, October 3, 2017

12:30 p.m.–3:00 p.m.

Grand Ballroom 3–4

**B54, PR13** TERT is frequently mutated in adult-type granulosa cell tumors of the ovary compared to other malignant sex cord-stromal tumors. Jessica Pilsworth, University of British Columbia, Vancouver, BC, Canada.

**B55** Recurrent transcriptional remodeling events and acquired fusion RNAs in relapsed ovarian cancers. Nolan Priedigkeit, University of Pittsburgh, Pittsburgh, PA, United States.

**B56** PTEN loss in the fallopian tube induces hyperplasia and ovarian tumor formation. Angela Russo, University of Illinois at Chicago, Chicago, IL, United States.

**B57** Adhesion and beyond: CD44 in ovarian cancer spheroids. Joelle Sacks, University of Illinois at Chicago, Chicago, IL, United States.

**B58** Progesterone receptor (PR) isoforms drive distinct cell-cell interactions and gene expression programs in human fallopian tube models of early HGSOC. Megan Seibel, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, United States.

**B59** Single-cell sequencing as a prognostic and predictive tool for ovarian cancer therapy. Timothy Starr, University of Minnesota, Minneapolis, MN, United States.

**B60** Systematic approach for identifying and validating novel therapies and targets for ovarian cancer. Alejandro Villar-Prados, UT MD Anderson Cancer Center, Houston, TX, United States.

**B61, PR14** CRISPR/Cas9-mediated Trp53, Brca1, Brca2, Pten, and Nf1 knockout to generate improved murine models of ovarian high grade serous carcinoma. Josephine Walton, The University of Glasgow, Glasgow, United Kingdom.

**B62** DDB2 represses ovarian cancer cell dedifferentiation by suppressing ALDH1A1. Qi-En Wang, The Ohio State University, Columbus, OH, United States.

**B63** The role of endometrium in endometriosis-associated ovarian cancer. Michael Wilson, Michigan State University, Grand Rapids, MI, United States.

**B64** The novel ZIP4 regulation and its role in cancer stem cell-related activities in ovarian cancer. Yan Xu, Indiana University School of Medicine, Indianapolis, IN, United States.

**B65** Modeling HGSOC using fallopian tube organoid cultures. Shuang Zhang, Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY, United States.

**B66** miRNA 3'UTR activity driven enrichment of ovarian tumor-initiating cells (TICs) to overcome the barriers of heterogeneity and TIC plasticity. Anil Belur Nagaraj, Case Western Reserve University, Cleveland, OH, United States.

**B67** Anti-tumor effect of black tea pigments, theaflavin-3/3'-gallate against cisplatin-resistant ovarian cancer cells. Yi Chen, Alderson Broaddus University, Philippi, WV, United States.
B68 Adnexal tumors associated with endometriosis: Experience from an academic institution. Mohamed Desouki, Vanderbilt University School of Medicine, Nashville, TN, United States.

B69 Intensive daily monitoring to identify onset, severity, and persistence of peripheral neuropathy following initiation of neurotoxic chemotherapy for women newly diagnosed with ovarian cancer. Heidi Donovan, University of Pittsburgh, Pittsburgh, PA, United States.

B70 Mathematical model quantifies the effect of novel combination therapies in high-grade serous ovarian cancer. Sampsa Hautaniemi, Faculty of Medicine, University of Helsinki, Helsinki, Finland.


B72 Credentialing ERalpha as target in high-grade serous ovarian cancer. Steffi Oesterreich, University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States.

B73 Activin A and activin C have opposing effects on pathways involved in cancer progression in Ovcar3 cells. Karen Reader, University of Otago, Dunedin, New Zealand.

B74 Identification of prognostic molecular subtypes of ovarian serous cystadenocarcinoma by isoform-level gene expression analysis. Arunima Shilpi, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.

B75 Modeling müllerian high-grade serous carcinogenesis using BRCA1 patient-derived induced pluripotent stem cells. Nur Yucer, Cedars Sinai Medical Center, Los Angeles, CA, United States.

B76 Oncogenic Kras and Pik3ca can cooperate with inactivation of various tumor suppressor genes to generate high-grade serous carcinomas in the mouse oviduct. Yali Zhai, University of Michigan, Ann Arbor, MI, United States.

B77 PAX8 is disseminated in sera of high grade serous ovarian carcinoma: A potential diseasespecific diagnostic biomarker. Pourya Naderi Yeganeh, University of North Carolina at Charlotte, Charlotte, NC, United States.